Cincinnati plays host to new cell, viral vector manufacturing site from Expression Therapeutics

Josh Sullivan

Expression Therapeutics’ new cell and viral vector manufacturing site is up and running in Cincinnati.

The 43,000 square-foot site will provide end-to-end R&D capabilities and both early phase- and commercial-scale manufacturing of lentiviral and adeno-associated viral vectors. The site will have a mix of 30-180 liter runs in cell stacks and up to 1,000 liter runs in bioreactors, with the capability to manufacture up to 100 products per year. It also gives the necessary infrastructure to fulfill its ex vivo cell processing, and recombinant protein production needs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Cincinnati plays host to new cell, viral vector manufacturing site from Expression Therapeutics

Josh Sullivan

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

House Oversight chair presses FDA on China amid growing tensions

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Cincin­nati plays host to new cell, vi­ral vec­tor man­u­fac­tur­ing site from Ex­pres­sion Ther­a­peu­tics

Josh Sullivan

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

House Over­sight chair press­es FDA on Chi­na amid grow­ing ten­sions

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Cincinnati plays host to new cell, viral vector manufacturing site from Expression Therapeutics

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

House Oversight chair presses FDA on China amid growing tensions

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients